Bank Of New York Mellon Corp 89bio, Inc. Transaction History
Bank Of New York Mellon Corp
- $538 Trillion
- Q3 2024
A detailed history of Bank Of New York Mellon Corp transactions in 89bio, Inc. stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 238,842 shares of ETNB stock, worth $2.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
238,842
Previous 299,689
20.3%
Holding current value
$2.11 Million
Previous $2.4 Billion
26.37%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ETNB
# of Institutions
159Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$134 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$125 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$70.5 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$65.1 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$61.9 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $410M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...